Placebo-controlled study of levetiracetam in idiopathic generalized epilepsy

Neurology

Volumn 69, Issue 18, 2007, Pages 1751-1760

  Berkovic, S F ^a,e   Knowlton, R C ^b   Leroy, R F ^c   Schiemann, J ^d   Falter, U ^d  

^a UNIVERSITY OF MELBOURNE   (Australia)

^b UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^c Neurological Clinic of Texas   (United States)

^d UCB PHARMA   (Belgium)

^e HEIDELBERG REPATRIATION HOSPITAL   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

CARBAMAZEPINE; ETIRACETAM; LAMOTRIGINE; PHENYTOIN; PLACEBO; TOPIRAMATE; VALPROIC ACID;

ADOLESCENT; ADULT; AGED; AGGRESSION; ARTICLE; BACKACHE; CHILD; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CONTUSION; CREATININE CLEARANCE; DEPRESSION; DIARRHEA; DIZZINESS; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG RESPONSE; DRUG TOLERABILITY; DRUG WITHDRAWAL; EOSINOPHIL COUNT; FATIGUE; FEMALE; GENERALIZED EPILEPSY; HEADACHE; HUMAN; INFLUENZA; IRRITABILITY; MAJOR CLINICAL STUDY; MALE; MENTAL DISEASE; MOOD CHANGE; MULTICENTER STUDY; NAUSEA; PARALLEL DESIGN; PRIORITY JOURNAL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; RETROSPECTIVE STUDY; RHINOPHARYNGITIS; SIDE EFFECT; SOMNOLENCE; SUICIDE ATTEMPT; TONIC CLONIC SEIZURE; TREATMENT OUTCOME; URINARY TRACT INFECTION;

EID: 35848938482     PISSN: 00283878     EISSN: None     Source Type: Journal    
DOI: 10.1212/01.wnl.0000268699.34614.d3     Document Type: Article

References (33)

1. International League Against Epilepsy. Proposal for revised classification of epilepsies and epileptic syndromes. Commission on Classification and Terminology of the International League Against Epilepsy. Epilepsia 1989;30:389-399.
2. Jallon P, Latour P. Epidemiology of idiopathic generalized epilepsies. Epilepsia 2005;46(suppl 9):10-14.
3. Benbadis SR. Practical management issues for idiopathic generalized epilepsies. Epilepsia 2005;46(suppl 9):125-132.
4. Marini C, Scheffer IE, Crossland KM, et al. Genetic architecture of idiopathic generalized epilepsy: clinical genetic analysis of 55 multiplex families. Epilepsia 2004;45:467-478.
5. Glauser T, Ben-Menachem E, Bourgeois B, et al. ILAE treatment guidelines: evidence-based analysis of antiepileptic drug efficacy and effectiveness as initial monotherapy for epileptic seizures and syndromes. Epilepsia 2006;47:1094-1120.
6. French JA, Kanner AM, Bautista J, et al. Efficacy and tolerability of the new antiepileptic drugs II: treatment of refractory epilepsy: report of the Therapeutics and Technology Assessment Subcommittee and Quality Standards Subcommittee of the American Academy of Neurology and the American Epilepsy Society. Neurology 2004;62:1261-1273.
7. Genton P. When antiepileptic drugs aggravate epilepsy. Brain Dev 2000;22:75-80.
8. Benbadis SR, Tatum WO 4th, Gieron M. Idiopathic generalized epilepsy and choice of antiepileptic drugs. Neurology 2003;61:1793-1795.
9. Beran RG, Berkovic SF, Dunagan FM, et al. Double-blind, placebo-controlled, crossover study of lamotrigine in treatment-resistant generalised epilepsy. Epilepsia 1998;39:1329-1333.
10. Biton V, Montouris GD, Ritter F, et al. A randomized, placebo-controlled study of topiramate in primary generalized tonic-clonic seizures. Topiramate YTC Study Group. Neurology 1999;52:1330-1337.
11. Biton V, Sackellares JC, Vuong A, Hammer AE, Barrett PS, Messenheimer JA. Double-blind, placebo-controlled study of lamotrigine in primary generalized tonic-clonic seizures. Neurology 2005;65:1737-1743.
12. Margineanu DG, Klitgaard H. Levetiracetam mechanism of action in antiepileptic drugs. In: Levy RH, Mattson RH, Meldrum BS, Perucca E, eds. Antiepileptic drugs, 5th ed. Philadelphia: Lippincott Williams & Wilkins; 2002:419-427.
13. Lynch BA, Lambeng N, Nocka K, et al. The synaptic vesicle protein SV2A is the binding site for the antiepileptic drug levetiracetam. Proc Natl Acad Sci USA 2004;101:9861-9866.
14. Ben-Menachem E, Falter U. Efficacy and tolerability of levetiracetam 3000 mg/d in patients with refractory partial seizures: a multicenter, double-blind, responder-selected study evaluating monotherapy. European Levetiracetam Study Group. Epilepsia 2000;41:1276-1283.
15. Cereghino JJ, Biton V, Abou-Khalil B, Dreifuss F, Gauer LJ, Leppik I. Levetiracetam for partial seizures: results of a double-blind, randomized clinical trial. Neurology 2000;55:236-242.
16. Shorvon SD, Lowenthal A, Janz D, Bielen E, Loiseau P. Multicenter double-blind, randomized, placebo-controlled trial of levetiracetam as add-on therapy in patients with refractory partial seizures. European Levetiracetam Study Group. Epilepsia 2000;41:1179-1186.
17. Morrell MJ, Leppik I, French J, Ferrendelli J, Han J, Magnus L. The KEEPER trial: levetiracetam adjunctive treatment of partial-onset seizures in an open-label community-based study. Epilepsy Res 2003;54:153-161.
18. Glauser TA, Ayala R, Elterman RD, et al., N159 Study Group. Double-blind placebo-controlled trial of adjunctive levetiracetam in pediatric partial seizures. Neurology 2006;66:1654-1660.
19. Verdru P, Wajgt A, Schiemann Delgado J, Noachtar S. Efficacy and safety of levetiracetam 3000 mg/d as adjunctive treatment in adolescents and adults suffering from idiopathic generalised epilepsy with myoclonic seizures. Epilepsia 2005;46(suppl 6):56-57. Abstract.
20. -1 in adult patients with refractory epilepsy. Seizure 2003;12:141-149.
21. Betts T, Yarrow H, Greenhill L, Barrett M. Clinical experience of marketed Levetiracetam in an epilepsy clinic - a one year follow up study. Seizure 2003;12:136-140.
22. Krauss GL, Betts T, Abou-Khalil B, Gergey G, Yarrow H, Miller A. Levetiracetam treatment of idiopathic generalised epilepsy. Seizure 2003;12:617-620.
23. Coppola G, Mangano S, Tortorella G, et al. Levetiracetam during 1-year follow-up in children, adolescents, and young adults with refractory epilepsy. Epilepsy Res 2004;59:35-42.
24. Grosso S, Franzoni E, Coppola G, et al. Efficacy and safety of levetiracetam: an add-on trial in children with refractory epilepsy. Seizure 2005;14:248-253.
25. Lagae L, Buyse G, Ceulemans B. Clinical experience with levetiracetam in childhood epilepsy: an add-on and mono-therapy trial. Seizure 2005;14:66-71.
26. Labate A, Colosimo E, Gambardella A, Leggio U, Ambrosio R, Quattrone A. Levetiracetam in patients with generalised epilepsy and myoclonic seizures: an open label study. Seizure 2006;15:214-218.
27. International Conference on Harmonisation Guideline for Good Clinical Practice (CPMP/ICH/135/95) [online]. Available at: www.ich.org. Accessed March 29, 2007.
28. Cramer J, Arrigo C, Van Hammée G. Patient-related priorities and relationship to distress in health-related quality of life domains: the QoLIE-31-P and QoLIE-10-P in a long-term levetiracetam study. Epilepsia 2002;43(suppl 8):199. Abstract.
29. French J, di Nicola S, Arrigo C. Fast and sustained efficacy of levetiracetam during titration and the first 3 months of treatment in refractory epilepsy. Epilepsia 2005;46:1304-1307.
30. Specchio LM, Gambardella A, Giallonardo AT, et al. Open label, long-term, pragmatic study on levetiracetam in the treatment of juvenile myoclonic epilepsy. Epilepsy Res 2006;71:32-39.
31. French J, Edrich P, Cramer JA. A systematic review of the safety profile of levetiracetam: a new antiepileptic drug. Epilepsy Res 2001;47:77-90.
32. Cramer JA, Arrigo C, Van Hammee G, Gauer LJ, Cereghino JJ. Effect of levetiracetam on epilepsy-related quality of life. N132 Study Group. Epilepsia 2000;41:868-874.
33. Patsalos PN. Pharmacokinetic profile of levetiracetam: toward ideal characteristics. Pharmacol Ther 2000;85:77-85.